The White House announced on 31 August that it had reached new agreements with 9 companies, including Astellas Pharma and Kyowa Kirin, concerning the most-favored-nation (MFN) policy for drug prices. As a result, drug prices under Medicaid, the health insurance program for low-income people, are expected to be reduced.
According to an announcement by the White House, new agreements have been reached with 9 companies, including Astellas Pharma and Kyowa Kirin, concerning the most-favored-nation (MFN) policy for drug prices. Details of the specific scope and conditions of application are quoted in the article, while no information is provided on when the policy will begin to apply. The news focuses on the expansion of agreements under the policy and plans to reduce prices for new drugs in the United States.
The companies covered include the Japanese companies Astellas Pharma and Kyowa Kirin, along with several others. These companies are reported to potentially be affected in setting drug prices in the United States under the MFN policy.